<p>Total Clarity Wealth Management Inc. 在最近向證券交易委員會提交的 13F 表格中表示，在第四季度購買了 Abivax SA Sponsored ADR (NASDAQ:ABVX - 免費報告) 的新股份。該基金購買了 9,245 股公司股票，價值約為 1,247,000 美元。</p>
<p>其他一些機構投資者也調整了他們對 ABVX 的持股。EverSource Wealth Advisors LLC 在第三季度將其在 Abivax 的持股增加了 4,612.5%。EverSource Wealth Advisors LLC 目前擁有 377 股公司股票，價值 32,000 美元，在此期間又購買了 369 股。First Horizon Corp 在第三季度以約 36,000 美元的價格收購了 Abivax 的新股份。美國銀行公司 DE 在第四季度將其在 Abivax 的持股增加了 56.1%。美國銀行公司 DE 目前擁有 5,536 股公司股票，價值 41,000 美元，在此期間又購買了 1,990 股。Hantz Financial Services Inc. 在第三季度以約 52,000 美元的價格收購了 Abivax 的新股份。最後，WPG Advisers LLC 在第四季度將其在 Abivax 的持股增加了 125.9%。WPG Advisers LLC 目前擁有 454 股公司股票，價值 61,000 美元，在此期間又購買了 253 股。機構投資者和對沖基金持有公司 47.91% 的股份。</p>
<h2>Abivax 股票表現</h2>
<p>Abivax 股票在週五開盤價為 117.38 美元。該公司的市值為 93.1 億美元，市盈率為 -21.86，貝塔值為 1.68。Abivax SA Sponsored ADR 的 52 周低點為 5.59 美元，52 周高點為 148.83 美元。該股票的 50 日移動平均線為 117.02 美元，200 日移動平均線為 116.30 美元。</p>
<p>Abivax (NASDAQ:ABVX - 獲取免費報告) 最近在 2 月 14 日星期六發布了其財報。公司報告該季度每股收益為 -1.20 美元。該業務在該季度的收入為 52 萬美元。作為一個整體，賣方分析師預測 Abivax SA Sponsored ADR 在當前財政年度將發佈 -3.84 的每股收益。</p>
<h2>華爾街分析師觀點</h2>
<p>一些研究分析師最近對該公司發佈了報告。Weiss Ratings 在 4 月 20 日的報告中重新發布了對 Abivax 股票的 &#34;賣出 (d-)&#34; 評級。花旗集團在 1 月 8 日的報告中重新發布了對 Abivax 股票的 &#34;市場表現優於大盤&#34; 評級。Oppenheimer 在 1 月 8 日的報告中對 Abivax 設定了 131.00 美元的目標價。BTIG Research 在 2 月 25 日的報告中重新發布了 &#34;買入&#34; 評級，並對 Abivax 股票設定了 150.00 美元的目標價。最後，Jefferies Financial Group 在 3 月 16 日的報告中開始覆蓋 Abivax。他們對該股票發佈了 &#34;買入&#34; 評級，並設定了 160.00 美元的目標價。一位研究分析師對該股票給予了強烈買入評級，十三位分析師給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat，該公司目前的平均評級為 &#34;適度買入&#34;，平均目標價為 137.15 美元。</p>
<p><strong>閲讀我們對 Abivax 的最新分析</strong></p>
<h2>Abivax 公司簡介</h2>
<p>(免費報告)</p>
<p>Abivax 成立於 2013 年，總部位於法國巴黎，是一家臨牀階段的生物製藥公司，專注於發現和開發針對慢性炎症性疾病和病毒感染的新療法。該公司的技術平台針對宿主 RNA 生物發生，以調節關鍵免疫通路，提供一種旨在疾病修飾和改善安全性特徵的差異化方法。</p>
<p>Abivax 的主要臨牀資產 obefazimod (ABX464) 正在評估用於潰瘍性結腸炎和其他炎症性疾病。</p>
<h2>瞭解更多</h2>
<ul>
<li>五隻我們更看好的股票超過 Abivax</li>
</ul>
<p><strong>想看看其他對沖基金持有的 ABVX 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Abivax SA Sponsored ADR (NASDAQ:ABVX - 免費報告) 的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Abivax 嗎？</h2>
<p>在你考慮 Abivax 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 Abivax 並不在名單上。</p>
<p>雖然 Abivax 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

ABVX

標普生物技術 3 倍做多 - Direxion

醫療業 ETF - Vanguard

<p>Total Clarity Wealth Management Inc. 在第四季度收購了 9,245 股 Abivax SA 贊助的 ADR（NASDAQ:ABVX），價值約為 125 萬美元。其他機構投資者也增加了對 Abivax 的持股，其中 EverSource Wealth Advisors 和美國銀行（Bank of America Corp DE）的增持尤為顯著。Abivax 的股票開盤價為 117.38 美元，市值為 93.1 億美元，市盈率為 -21.86。分析師對該股票的評級不一，平均目標價為 137.15 美元</p>

<p>Total Clarity Wealth Management Inc. bought a new stake in Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities &amp; Exchange Commission. The fund bought 9,245 shares of the company's stock, valued at approximately $1,247,000.</p>
<div class="lb-trans"><p>Total Clarity Wealth Management Inc. 在最近向證券交易委員會提交的 13F 表格中表示，在第四季度購買了 Abivax SA Sponsored ADR (NASDAQ:ABVX - 免費報告) 的新股份。該基金購買了 9,245 股公司股票，價值約為 1,247,000 美元。</p>
</div><p>A number of other institutional investors have also modified their holdings of ABVX. EverSource Wealth Advisors LLC increased its holdings in shares of Abivax by 4,612.5% in the third quarter. EverSource Wealth Advisors LLC now owns 377 shares of the company's stock valued at $32,000 after purchasing an additional 369 shares during the period. First Horizon Corp acquired a new position in shares of Abivax in the third quarter valued at approximately $36,000. Bank of America Corp DE increased its holdings in shares of Abivax by 56.1% in the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock valued at $41,000 after purchasing an additional 1,990 shares during the period. Hantz Financial Services Inc. acquired a new position in shares of Abivax in the third quarter valued at approximately $52,000. Finally, WPG Advisers LLC increased its holdings in shares of Abivax by 125.9% in the fourth quarter. WPG Advisers LLC now owns 454 shares of the company's stock valued at $61,000 after purchasing an additional 253 shares during the period. Institutional investors and hedge funds own 47.91% of the company's stock.</p>
<div class="lb-trans"><p>其他一些機構投資者也調整了他們對 ABVX 的持股。EverSource Wealth Advisors LLC 在第三季度將其在 Abivax 的持股增加了 4,612.5%。EverSource Wealth Advisors LLC 目前擁有 377 股公司股票，價值 32,000 美元，在此期間又購買了 369 股。First Horizon Corp 在第三季度以約 36,000 美元的價格收購了 Abivax 的新股份。美國銀行公司 DE 在第四季度將其在 Abivax 的持股增加了 56.1%。美國銀行公司 DE 目前擁有 5,536 股公司股票，價值 41,000 美元，在此期間又購買了 1,990 股。Hantz Financial Services Inc. 在第三季度以約 52,000 美元的價格收購了 Abivax 的新股份。最後，WPG Advisers LLC 在第四季度將其在 Abivax 的持股增加了 125.9%。WPG Advisers LLC 目前擁有 454 股公司股票，價值 61,000 美元，在此期間又購買了 253 股。機構投資者和對沖基金持有公司 47.91% 的股份。</p>
</div><h2>Abivax Stock Performance</h2>
<div class="lb-trans"><h2>Abivax 股票表現</h2>
</div><p>Abivax stock opened at $117.38 on Friday. The firm has a market capitalization of $9.31 billion, a price-to-earnings ratio of -21.86 and a beta of 1.68. Abivax SA Sponsored ADR has a fifty-two week low of $5.59 and a fifty-two week high of $148.83. The stock's fifty day moving average is $117.02 and its two-hundred day moving average is $116.30.</p>
<div class="lb-trans"><p>Abivax 股票在週五開盤價為 117.38 美元。該公司的市值為 93.1 億美元，市盈率為 -21.86，貝塔值為 1.68。Abivax SA Sponsored ADR 的 52 周低點為 5.59 美元，52 周高點為 148.83 美元。該股票的 50 日移動平均線為 117.02 美元，200 日移動平均線為 116.30 美元。</p>
</div><p>Abivax (NASDAQ:ABVX - Get Free Report) last posted its earnings results on Saturday, February 14th. The company reported ($1.20) earnings per share for the quarter. The business had revenue of $0.52 million during the quarter. As a group, sell-side analysts forecast that Abivax SA Sponsored ADR will post -3.84 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Abivax (NASDAQ:ABVX - 獲取免費報告) 最近在 2 月 14 日星期六發布了其財報。公司報告該季度每股收益為 -1.20 美元。該業務在該季度的收入為 52 萬美元。作為一個整體，賣方分析師預測 Abivax SA Sponsored ADR 在當前財政年度將發佈 -3.84 的每股收益。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>華爾街分析師觀點</h2>
</div><p>A number of research analysts have recently issued reports on the company. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Abivax in a report on Monday, April 20th. Citigroup reissued a &#34;market outperform&#34; rating on shares of Abivax in a report on Thursday, January 8th. Oppenheimer set a $131.00 target price on Abivax in a report on Thursday, January 8th. BTIG Research reissued a &#34;buy&#34; rating and issued a $150.00 target price on shares of Abivax in a report on Wednesday, February 25th. Finally, Jefferies Financial Group assumed coverage on Abivax in a report on Monday, March 16th. They issued a &#34;buy&#34; rating and a $160.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $137.15.</p>
<div class="lb-trans"><p>一些研究分析師最近對該公司發佈了報告。Weiss Ratings 在 4 月 20 日的報告中重新發布了對 Abivax 股票的 &#34;賣出 (d-)&#34; 評級。花旗集團在 1 月 8 日的報告中重新發布了對 Abivax 股票的 &#34;市場表現優於大盤&#34; 評級。Oppenheimer 在 1 月 8 日的報告中對 Abivax 設定了 131.00 美元的目標價。BTIG Research 在 2 月 25 日的報告中重新發布了 &#34;買入&#34; 評級，並對 Abivax 股票設定了 150.00 美元的目標價。最後，Jefferies Financial Group 在 3 月 16 日的報告中開始覆蓋 Abivax。他們對該股票發佈了 &#34;買入&#34; 評級，並設定了 160.00 美元的目標價。一位研究分析師對該股票給予了強烈買入評級，十三位分析師給予了買入評級，一位分析師給予了賣出評級。根據 MarketBeat，該公司目前的平均評級為 &#34;適度買入&#34;，平均目標價為 137.15 美元。</p>
</div><p><strong>Read Our Latest Analysis on Abivax</strong></p>
<div class="lb-trans"><p><strong>閲讀我們對 Abivax 的最新分析</strong></p>
</div><h2>Abivax Company Profile</h2>
<div class="lb-trans"><h2>Abivax 公司簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>(免費報告)</p>
</div><p>Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.</p>
<div class="lb-trans"><p>Abivax 成立於 2013 年，總部位於法國巴黎，是一家臨牀階段的生物製藥公司，專注於發現和開發針對慢性炎症性疾病和病毒感染的新療法。該公司的技術平台針對宿主 RNA 生物發生，以調節關鍵免疫通路，提供一種旨在疾病修飾和改善安全性特徵的差異化方法。</p>
</div><p>Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.</p>
<div class="lb-trans"><p>Abivax 的主要臨牀資產 obefazimod (ABX464) 正在評估用於潰瘍性結腸炎和其他炎症性疾病。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>瞭解更多</h2>
</div><ul>
<li>Five stocks we like better than Abivax</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票超過 Abivax</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding ABVX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對沖基金持有的 ABVX 嗎？</strong> 訪問 HoldingsChannel.com 獲取 Abivax SA Sponsored ADR (NASDAQ:ABVX - 免費報告) 的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJWWA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=ABVX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Abivax Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Abivax 嗎？</h2>
</div><p>Before you consider Abivax, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Abivax 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買... 而 Abivax 並不在名單上。</p>
</div><p>While Abivax currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Abivax 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Total Clarity Wealth Management Inc. Acquires Shares of 9,245 Abivax SA Sponsored ADR $ABVX

Market Beat

Abivax SA

2 倍做多納斯達克生物技術 ETF - ProShares

美國制藥 ETF - iShares

動態生物技術與基因組 ETF - Invesco

標普生物技術 ETF - SPDR

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

醫藥突破 ETF - ALPS

納斯達克生物科技指數 ETF - iShares Nasdaq

第一地平線

美國銀行

花旗

奧本海默控股

Jefferies Financial

FIRST HORIZON CORPORATION 6.50% DEP SHS REP 1/4000 PER PFD SER E

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER C

FIRST HORIZON CORPORATION DEP SHS REP 1/400 NON CUM PER PFD SER B

FIRST HORIZON CORPORATION DEP SH REP 1/4000 INT NON CUM PFD H WI

FIRST HORIZON CORPORATION DEP SHS REPSTG 1/4000TH PERP PFD SER F

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Total Clarity Wealth Management Inc. 收購了 9,245 股 Abivax SA 贊助的美國存託憑證 $ABVX